How would you approach systemic management of a patient with an early aggressive metastatic relapse of previously early stage triple negative disease in breast only but now with multiple distant metastatic sites (including contralateral breast) which is now high ER expressing?

She had a ipsilateral chest wall recurrence after mastectomy ~5 wks after surgery that was known TNBC. Residual disease remained in known breast and axilla, but now new disease involving the contralateral breast that was proven to be ER+ with poor differentiation. PD-L1 testing is negative.

Answer from: Medical Oncologist at Academic Institution

There isn't sufficient information to answer your question succinctly. Did she receive neoadjuvant chemotherapy, and, if so, how did she respond? Have you biopsied a metastatic site other than the contralateral breast? if not, you should, to assess its ER expression. Even if she is PD-L1 p...

Please select the option that best describes you:

How would you approach systemic management of a patient with an early aggressive metastatic relapse of previously early stage triple negative disease in breast only but now with multiple distant metastatic sites (including contralateral breast) which is now high ER expressing?

Related Questions